Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients.

advanced glycation end products colorectal cancer glyceraldehyde-derived advanced glycation end products mortality prospective study

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 06 2023
Historique:
revised: 05 12 2022
received: 25 07 2022
accepted: 12 12 2022
medline: 6 4 2023
pubmed: 31 1 2023
entrez: 30 1 2023
Statut: ppublish

Résumé

Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HR

Identifiants

pubmed: 36715363
doi: 10.1002/ijc.34449
doi:

Substances chimiques

Glycation End Products, Advanced 0
Glyceraldehyde 367-47-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2257-2268

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-UU_12015/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C864/A14136
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A29017
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom

Informations de copyright

© 2023 UICC.

Références

International Agency for Research on Cancer WHO. The Global Cancer Observatory-Cancer today; 2020. https://gco.iarc.fr/today/home.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Zoltick ES, Smith-Warner SA, Yuan C, et al. Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival. Br J Cancer. 2021;125(7):1016-1024.
Takeuchi M. Serum levels of toxic AGEs (TAGE) may Be a promising novel biomarker for the onset/progression of lifestyle-related diseases. Diagnostics. 2016;6(2):23.
Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70(2):138-151.
Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses. 2004;63(3):449-452.
Senavirathna L, Ma C, Chen R, Pan S. Proteomic investigation of glyceraldehyde-derived intracellular AGEs and their potential influence on pancreatic ductal cells. Cells. 2021;10(5):1005.
Takeuchi M, Sakasai-Sakai A, Takata T, et al. Intracellular toxic AGEs (TAGE) triggers numerous types of cell damage. Biomolecules. 2021;11(3):387.
Takeuchi M. Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle. Diabetol Metab Syndr. 2020;12(1):105.
O'Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr. 1989;28(3):211-248.
Meyerhardt JA, Sato K, Niedzwiecki D, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012;104(22):1702-1711.
Fuchs MA, Sato K, Niedzwiecki D, et al. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014;9(6):e99816.
Guercio BJ, Zhang S, Niedzwiecki D, et al. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018;13(7):e0199244.
Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8(7):337-346.
Stone WL, Krishnan K, Campbell SE, Palau VE. The role of antioxidants and pro-oxidants in colon cancer. World J Gastrointest Oncol. 2014;6(3):55-66.
van Harten-Gerritsen AS, Balvers MG, Witkamp RF, Kampman E, van Duijnhoven FJ. Vitamin D, inflammation, and colorectal cancer progression: a review of mechanistic studies and future directions for epidemiological studies. Cancer Epidemiol Biomark Prev. 2015;24(12):1820-1828.
Boakye D, Jansen L, Schoettker B, et al. Blood markers of oxidative stress are strongly associated with poorer prognosis in colorectal cancer patients. Int J Cancer. 2020;147(9):2373-2386.
Takeuchi M, Takino J, Yamagishi S. Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy. J Ophthalmol. 2010;2010:170393.
Dariya B, Nagaraju GP. Advanced glycation end products in diabetes, cancer and phytochemical therapy. Drug Discov Today. 2020;25(9):1614-1623.
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res. 2013;45(5):387-390.
Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25(11):2185-2197.
Liang H. Advanced glycation end products induce proliferation, invasion and epithelial-mesenchymal transition of human SW480 colon cancer cells through the PI3K/AKT signaling pathway. Oncol Lett. 2020;19(4):3215-3222.
Grillo M, Colombatto S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids. 2008;35(1):29-36.
Chang C-C, Chen C-Y, Chang G-D, et al. Hyperglycemia and advanced glycation end products (AGEs) suppress the differentiation of 3T3-L1 preadipocytes. Oncotarget. 2017;8(33):55039-55050.
Cheng H-C, Chang T-K, Su W-C, Tsai H-L, Wang J-Y. Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. Transl Oncol. 2021;14(7):101089.
Siddiqui AA, Palmer BF. Metabolic syndrome and its association with colorectal cancer: a review. Am J Med Sci. 2011;341(3):227-231.
Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med. 2006;6(3):351-358.
Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis. 2009;16(4):845-858.
Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2006;21(3):197-208.
Kong SY, Takeuchi M, Hyogo H, et al. The association between glyceraldehyde-derived advanced glycation end-products and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2015;24(12):1855-1863.
Riboli E, Hunt KJ, Slimani N, et al. European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6b):1113-1124.
Bingham S, Riboli E. Diet and cancer-the European prospective investigation into cancer and nutrition. Nat Rev Cancer. 2004;4(3):206-215.
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med. 2000;6(2):114-125.
Tahara N, Yamagishi S-i, Takeuchi M, et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [18F] fluorodeoxyglucose positron emission tomography. Diabetes Care. 2012;35(12):2618-2625.
Jinno M, Takeuchi M, Watanabe A, et al. Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod. 2011;26(3):604-610.
Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551-561.
Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA. Comparing smoothing techniques in cox models for exposure-response relationships. Stat Med. 2007;26(20):3735-3752.
Li R, Hertzmark E, Louie M, Chen L, Spiegelman D. The Sas lgtphcurv9 Macro. Boston: Channing Laboratory; 2011.
Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q. Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One. 2013;8(5):e63702.
Vlassara H, Cai W, Tripp E, et al. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia. 2016;59(10):2181-2192.
Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA. 2002;99(24):15596-15601.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129-146.
Usui T, Shizuuchi S, Watanabe H, Hayase F. Cytotoxicity and oxidative stress induced by the glyceraldehyde-related Maillard reaction products for HL-60 cells. Biosci Biotechnol Biochem. 2004;68(2):333-340.
Yamagishi S, Amano S, Inagaki Y, et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun. 2002;290(3):973-978.
Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370(Pt 3):1097-1109.
Yamamoto Y, Yonekura H, Watanabe T, et al. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract. 2007;77(Suppl 1):S30-S40.
Abe R, Shimizu T, Sugawara H, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol. 2004;122(2):461-467.
Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol. 2010;2010:739852.
Mao Z, Aglago EK, Zhao Z, et al. Dietary intake of advanced glycation end products (AGEs) and mortality among individuals with colorectal cancer. Nutrients. 2021;13(12):4435.
Peterson LL, Omofuma O, Turner DP, et al. Dietary advanced glycation end products (AGEs) and breast cancer mortality in the women's health initiative (WHI). J Clin Oncol. 2020;38(15_suppl):1570.
Bettiga A, Fiorio F, Di Marco F, et al. The modern Western diet rich in advanced glycation end-products (AGEs): an overview of its impact on obesity and early progression of renal pathology. Nutrients. 2019;11(8):1748.
Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111-2117.
Uribarri J, Cai W, Woodward M, et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? J Clin Endocrinol Metab. 2015;100(5):1957-1966.
Snelson M, Coughlan MT. Dietary advanced glycation end products: digestion, metabolism and modulation of gut microbial ecology. Nutrients. 2019;11(2):215.
Zhong M, Xiong Y, Ye Z, et al. Microbial community profiling distinguishes left-sided and right-sided colon cancer. Front Cell Infect Microbiol. 2020;10:498502.
Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20.
Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003;93(12):1159-1169.

Auteurs

Ziling Mao (Z)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Jacqueline Roshelli Baker (JR)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Masayoshi Takeuchi (M)

Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.

Hideyuki Hyogo (H)

Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
Lifecare Clinic Hiroshima, Hiroshima, Japan.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Diet, Cancer and Health, Copenhagen, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Anne Kirstine Eriksen (AK)

Danish Cancer Society Research Center, Diet, Cancer and Health, Copenhagen, Denmark.

Gianluca Severi (G)

UVSQ, Inserm, Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Université Paris-Saclay, Villejuif, France.
Department of Statistics, Computer Science Applications, "G. Parenti" University of Florence, Florence, Italy.

Joseph Rothwell (J)

UVSQ, Inserm, Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Université Paris-Saclay, Villejuif, France.

Nasser Laouali (N)

UVSQ, Inserm, Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Université Paris-Saclay, Villejuif, France.

Verena Katzke (V)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.

Domenico Palli (D)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Sabina Sieri (S)

Epidemiology and Prevention Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano Via Venezian, Milan, Italy.

Maria Santucci de Magistris (MS)

Azienda Ospedaliera Universitaria Federico II, Naples, Italy.

Rosario Tumino (R)

Hyblean Association for Epidemiological Research, AIRE ONLUS, Ragusa, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy.

Jeroen W G Derksen (JWG)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Inger T Gram (IT)

Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.

Guri Skeie (G)

Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.

Torkjel M Sandanger (TM)

Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.

Jose Ramón Quirós (JR)

Public Health Directorate, Asturias, Spain.

Marta Crous-Bou (M)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Maria-Jose Sánchez (MJ)

Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.

Pilar Amiano (P)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain.
Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain.

Sandra M Colorado-Yohar (SM)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.

Marcela Guevara (M)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Sophia Harlid (S)

Department of Radiation Sciences, Umeå University, Umeå, Sweden.

Ingegerd Johansson (I)

Department of Odontology, Umeå university, Umeå, Sweden.

Aurora Perez-Cornago (A)

Cancer Epidemiology Unit (CEU), Nuffield Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, UK.

Heinz Freisling (H)

Section of Nutrition and Metabolism, Nutritional Epidemiology Group, International Agency for Research on Cancer, World Health Organization (IARC-WHO), Lyon, France.

Marc Gunter (M)

Section of Nutrition and Metabolism, Nutritional Epidemiology Group, International Agency for Research on Cancer, World Health Organization (IARC-WHO), Lyon, France.

Elisabete Weiderpass (E)

Office of the Director, International Agency for Research on Cancer (IARC-WHO), Lyon, France.

Alicia K Heath (AK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Elom Aglago (E)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Mazda Jenab (M)

Section of Nutrition and Metabolism, Nutritional Epidemiology Group, International Agency for Research on Cancer, World Health Organization (IARC-WHO), Lyon, France.

Veronika Fedirko (V)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
MD Anderson Cancer Center, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH